nach oben

Erschienen in:

01.01.2010 | Clinical trial

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

verfasst von: Amadeo M. Parissenti, Judy-Anne W. Chapman, Harriette J. Kahn, Baoqing Guo, Lei Han, Patti O’Brien, Mark P. Clemons, Roberta Jong, Rebecca Dent, Barbara Fitzgerald, Kathleen I. Pritchard, Lois E. Shepherd, Maureen E. Trudeau

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

The CAN-NCIC-MA22 phase I/II clinical trial evaluated women with locally advanced or inflammatory breast cancer treated with epirubicin and docetaxel at 2 or 3 weekly intervals in sequential cohorts. The relationship between various biomarkers and treatment response was assessed. Breast biopsy cores were obtained from 50 patients pre-, mid-, and post-treatment. Immunohistochemical staining was performed to determine baseline levels of estrogen receptor (ER), progesterone receptor (PR), Her2/Neu protein (HER2), and topoisomerase II (Topo 2), expressed as percent positive stain. Tumor RNA integrity (RIN) and tumor cellularity were measured pre-, mid- and post-treatment by capillary electrophoresis and light microscopy after hematoxylin/eosin staining, respectively. Associations between 1) maximum RIN and 2) tumor cellularity at the three time points with baseline levels of ER, PR, Her2, and topo II were assessed using Spearman and Pearson correlation coefficients. Associations between RIN and tumor cellularity with chemotherapy dose level or pathologic response were assessed using one-way ANOVA. In this study, we observed that low mid-treatment maximum RIN (but not tumor cellularity) was associated with high chemotherapy drug dose level (P = 0.05) and eventual pathologic complete response (pCR) (P = 0.01). Post-treatment, low maximum RIN was found to be associated with low tumor cellularity (P = 0.004), and low tumor cellularity with pCR (P = 0.01). Post-treatment tumor cellularity was lowest in patients with tumors having high baseline PR levels (P = 0.05). The association of mid-treatment RIN with drug dose level and with pCR suggests that tumor RIN may represent an important new biomarker for measuring response to chemotherapy in breast cancer patients.

Zijlstra JG, de Jong S, de Vries EG, Mulder NH (1990) Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7(1):11–18PubMed

Richardson DS, Johnson SA (1997) Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11(4):201–223CrossRefPubMed

Capranico G, Tinelli S, Zunino F (1989) Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chem Biol Interact 72(1–2):113–123CrossRefPubMed

Chazard M, Pellae-Cosset B, Garet F, Soares JA, Lucidi B, Lavail Y et al (1994) Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes. Bull Cancer 81(3):173–181PubMed

Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A et al (1997) Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 72(5):844–850CrossRefPubMed

Moos PJ, Fitzpatrick FA (1998) Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95(7):3896–3901CrossRefPubMed

Weinstein RS, Kuszak JR, Kluskens LF, Coon JS (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21(1):34–48CrossRefPubMed

Kerbel RS, Kobayashi H, Graham CH (1994) Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56(1):37–47CrossRefPubMed

Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152–162CrossRefPubMed

10.

Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39(6 Pt 1):2070–2076PubMed

11.

Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 258(5088):1650–1654CrossRefPubMed

12.

Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA et al (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51(24):6592–6595PubMed

13.

Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52(7):1666–1674PubMed

14.

Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, Meltzer SJ (1995) p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. Radiat Res 142(3):256–262CrossRefPubMed

15.

Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2(7):811–814CrossRefPubMed

16.

Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH (1986) Overexpression of a novel anionic glutathione transferase in multidrug- resistant human breast cancer cells. J Biol Chem 261(33):15544–15549PubMed

17.

Batist G, Behrens BC, Makuch R, Hamilton TC, Katki AG, Louie KG et al (1986) Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochem Pharmacol 35(13):2257–2259CrossRefPubMed

18.

Harris AL, Hochhauser D (1992) Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31(2):205–213CrossRefPubMed

19.

Cabral F, Abraham I, Gottesman MM (1981) Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci USA 78(7):4388–4391CrossRefPubMed

20.

Schibler MJ, Huang B (1991) The colR4 and colR15 beta-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability. J Cell Biol 113(3):605–614CrossRefPubMed

21.

Weber WA, Schwaiger M, Avril N (2000) Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27(7):683–687CrossRefPubMed

22.

Kim SJ, Kim SK, Lee ES, Ro J, Kang S (2004) Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15(9):1352–1357CrossRefPubMed

23.

McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102(1):75–84CrossRefPubMed

24.

Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98(3):267–274CrossRefPubMed

25.

Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18(20):3495–3502PubMed

26.

Lim HS, Yoon W, Chung TW, Kim JK, Park JG, Kang HK et al (2007) FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 27(Suppl 1):S197–S213CrossRefPubMed

27.

de Vos FY, Willemse PH, de Vries EG, Gietema JA (2004) Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 30(6):495–513CrossRefPubMed

28.

Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M et al (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7:3CrossRefPubMed

29.

Weis S, Llenos IC, Dulay JR, Elashoff M, Martinez-Murillo F, Miller CL (2007) Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods 165(2):198–209CrossRefPubMed

30.

Strand C, Enell J, Hedenfalk I, Ferno M (2007) RNA quality in frozen breast cancer samples and the influence on gene expression analysis–a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol Biol 8:38CrossRefPubMed

31.

Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW (2006) Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT–PCR. Biotechnol Lett 28(19):1601–1613CrossRefPubMed

32.

Box GEP, Cox DR (1964) Analysis of transformations. J Roy Stat Soc Ser Bull 26:211–252

33.

Daoust R, De LG (1975) Ribonucleases and neoplasia. Subcell Biochem 4(3):185–211PubMed

34.

King KL, Jewell CM, Bortner CD, Cidlowski JA (2000) 28S ribosome degradation in lymphoid cell apoptosis: evidence for caspase and Bcl-2-dependent and-independent pathways. Cell Death Differ 7(10):994–1001CrossRefPubMed

35.

Irie M (1999) Structure–function relationships of acid ribonucleases: lysosomal, vacuolar, and periplasmic enzymes. Pharmacol Ther 81(2):77–89CrossRefPubMed

36.

Maragoudakis ME, Peristeris P, Missirlis E, Aletras A, Andriopoulou P, Haralabopoulos G (1994) Inhibition of angiogenesis by anthracyclines and titanocene dichloride. Ann N Y Acad Sci 732:280–293CrossRefPubMed

37.

Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121–129CrossRefPubMed

38.

Zhang XS, Zhu XF, Gao JS, Ye YL, Feng QS, Liu ZC et al (2002) Variable sensitivity of endothelial cells to epirubicin in xenografts of human nasopharyngeal carcinoma CNE-2 cells. Cancer Biol Ther 1(3):263–265PubMed

Titel: Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
verfasst von: Amadeo M. Parissenti
Judy-Anne W. Chapman
Harriette J. Kahn
Baoqing Guo
Lei Han
Patti O’Brien
Mark P. Clemons
Roberta Jong
Rebecca Dent
Barbara Fitzgerald
Kathleen I. Pritchard
Lois E. Shepherd
Maureen E. Trudeau
Publikationsdatum: 01.01.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0531-x

Springer Medizin

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Erratum to: Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women

ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy

Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue

Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-β1 and TNF-α

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2

Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie